Home » Newsletters » BioWorld Science

BioWorld Science

July 28, 1999

View Archived Issues

Forest restructures Climara agreement with Berlex

Medeva announces half-year highlights

Early-stage R&D at BioCryst: Q2 highlights

Rochester Medical's female incontinence device receives CE mark

Avant's complement-selectin inhibitor reduces brain damage in mouse model of stroke

Eligix cleared to initiate pivotal trial of DLI purification technology

Kos and Knoll reach definitive agreement for promotion of antihypertensive drugs

Kinetek initiates development of ILK and PKB inhibitors for cancer therapy

Biovail to acquire Fuisz

FDA approves pediatric formulation of Topamax

Heterocyclic compounds as potent and selective NK2 antagonists

Asmarine A and B: novel cytotoxic alkaloids produced by marine organism

Novel epipodophyllotoxin derivatives with excellent antitumor activity

Potassium channel modulators designed at Novo Nordisk especially for endocrine disorders

Dopaminergic agents for schizophrenia and Parkinson's disease from AHP

Warner-Lambert patents new series of dopamine D4 antagonists

International patent recently published covering AstraZeneca PKC inhibitors

Mechanism of gastroprotective effects of lafutidine determined in in vitro and in vivo studies

Postischemic YM-872 investigated for neuroprotective effects in model of acute ischemic stroke

NS-49: preclinical pharmacokinetics of potential new agent for stress incontinence

Shire and Roberts enter definitive merger agreement

Elan and Merck establish second technology transfer and license agreement

Schering-Plough launches Rebetol combination therapy in the U.K.

FDA advisory committee OKs safety and efficacy of Rapamune

FDA approves Relenza for treatment of influenza

Second U.S. patent covers GVAX cancer vaccine technology; positive lung cancer results reported

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 23, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...